By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on

Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 7,300+ Worldwide
Symbol: AMGN


Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax  Antibody phage display

Company News
Takeda (TKPYY) Returns Certain Molecules, Products to Amgen (AMGN) 6/24/2016 5:58:40 AM
Two Bay Area Startups Win Amgen (AMGN)'s Golden Ticket Award 6/23/2016 5:34:30 AM
Amgen (AMGN) Appoints Esteban Santos Executive Vice President, Operations 6/20/2016 6:34:24 AM
Amgen (AMGN) Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab 6/14/2016 1:11:17 PM
Amgen (AMGN) Release: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression 6/13/2016 10:49:06 AM
Amgen (AMGN) Announces Expiration And Final Results Of Senior Notes Exchange Offers 6/10/2016 9:40:26 AM
Amgen (AMGN) Release: BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia 6/10/2016 8:55:37 AM
Amgen (AMGN) Shows Off Mid-Stage Migraine Data, Needs to Compete With Eli Lilly (LLY), Teva (TEVA) and Alder Biopharma 6/9/2016 5:54:09 AM
ASCO2016: Amgen (AMGN) Release: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen 6/7/2016 8:34:12 AM
Amgen (AMGN) Announces Launch Of KYPROLIS (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers 6/6/2016 12:03:27 PM